RANKL
Evidence: B — Meaningful Human EvidenceEndocrine / Calcium-Bone Axis Signaling
Evidence Snapshot
What this grade covers
B reflects strong human genetic evidence (Sobacchi 2007) and mechanistic pathway literature. This grade's strength comes entirely from genetic/mechanistic evidence, not from any administration or denosumab-derived component. RANK (TNFRSF11A) is a distinct receptor gene and is used only as boundary/receptor context, never as a substitute for direct RANKL evidence.
Regulatory Context
Native RANKL is an endogenous cytokine with no approved product of its own; there is no rational therapeutic case for administering RANKL. Denosumab (Prolia) is an FDA-approved monoclonal antibody that blocks RANKL, a separate, firewalled target-inhibition context.
Research Takeaway
Loss-of-function mutations in TNFSF11 (RANKL) cause a rare, osteoclast-poor form of autosomal-recessive osteopetrosis in humans; exogenous RANKL restored functional osteoclast formation from patients' monocytes in vitro, demonstrating RANKL's essential role in osteoclast differentiation.
See all 4 evidence claims →Quick Summary
RANKL is the main signal that tells the body to activate bone-resorbing cells. Rare human genetic conditions where its absence prevents bone resorption demonstrate its role; an approved antibody drug (denosumab) blocks it to treat osteoporosis, but there is no established use for administering RANKL itself.
Mechanism & Research Overview
RANKL is the main signal that tells the body to activate bone-resorbing cells. Rare human genetic conditions where its absence prevents bone resorption demonstrate its role; an approved antibody drug (denosumab) blocks it to treat osteoporosis, but there is no established use for administering RANKL itself.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Loss-of-function mutations in TNFSF11 (RANKL) cause a rare, osteoclast-poor form of autosomal-recessive osteopetrosis in humans; exogenous RANKL restored functional osteoclast formation from patients' monocytes in vitro, demonstrating RANKL's essential role in osteoclast differentiation.
Sources: Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Supported
Unlike osteopetrosis caused by mutations in the RANKL receptor gene TNFRSF11A (RANK), RANKL-deficient osteopetrosis was not cured by hematopoietic stem cell transplantation in the reported cases.
Sources: Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Supported
RANK (TNFRSF11A), the receptor RANKL signals through, is a distinct gene and protein from RANKL itself; RANK-deficient osteopetrosis (associated with hypogammaglobulinemia) is a clinically distinct disease from RANKL-deficient osteopetrosis.
Does not establish
Evidence boundary: RECEPTOR_CONTEXT boundary source only, not a substitute for direct RANKL genetic evidence.
Sources: Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations
Supported
Denosumab, a monoclonal antibody that binds and neutralizes RANKL, is FDA-approved for osteoporosis and reduced vertebral, hip, and nonvertebral fracture incidence in the pivotal FREEDOM trial (N=7,868).
Does not establish
Evidence boundary: This is evidence about denosumab's efficacy in inhibiting RANKL signaling, not evidence that administering RANKL itself has any therapeutic use.
Sources: PROLIA (denosumab) — FDA Prescribing Information / FREEDOM Trial
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
RANK (receptor, TNFRSF11A) and RANKL (ligand, TNFSF11) are frequently confused; RANK-deficient and RANKL-deficient osteopetrosis are clinically distinct.Safety Consideration
FREEDOM trial fracture-reduction data belongs to denosumab, not to any claim about administering RANKL.Safety Consideration
There is no rational therapeutic case for administering native RANKL, which promotes bone resorption; this lane is structurally absent.
Research Areas Being Studied
Research areas discussed on this page reflect the Endocrine / Calcium-Bone Axis Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations (2008):
- Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL (2007):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations | 2008 | RANK (TNFRSF11A), the receptor RANKL signals through, is a distinct gene/protein from RANKL. RANK-deficient osteopetrosis is a clinically distinct disease (associated with hypogammaglobulinemia) from RANKL-deficient osteopetrosis, and unlike it, is HSCT-responsive. RECEPTOR_CONTEXT boundary source only, not a substitute for direct RANKL genetic evidence. | |||
| Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL | 2007 | Loss-of-function mutations in TNFSF11 (RANKL) cause a rare, osteoclast-poor form of autosomal-recessive osteopetrosis in 6 individuals; unlike RANK(TNFRSF11A)-deficient osteopetrosis, which is HSCT-responsive, RANKL-deficient osteopetrosis was NOT cured by hematopoietic stem cell transplantation in the reported cases, though exogenous RANKL restored functional osteoclast formation from patients' monocytes in vitro. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| PROLIA (denosumab) — FDA Prescribing Information / FREEDOM Trial | Denosumab is a monoclonal antibody that binds and neutralizes RANKL, FDA-approved for postmenopausal osteoporosis. In the pivotal FREEDOM trial (N=7,868), denosumab improved BMD (9.2% lumbar spine, 6.0% hip) and reduced vertebral (68%), hip (40%), and nonvertebral (20%) fracture incidence versus placebo at 3 years. TARGET_INHIBITION_CONTEXT: evidence about denosumab's efficacy in blocking RANKL signaling, never evidence that administering RANKL itself has therapeutic use. | No source link available |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and official regulatory information about RANKL and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for RANKL
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.